The new drug is called Tofacitinib which is part of a new class of drugs called Janus kinases which early research indicates may be more effective at treating rheumatoid arthritis than  the current drugs on the market, such as the commonly prescribed methotrexate (MTX). The drug is still not approved in the US but hopefully these early trials will lead to some new and much needed remedy for chronic joint pain.